San­doz pays out $265M to set­tle part of an­titrust law­suit

San­doz and its sub­sidiary Fougera Phar­ma­ceu­ti­cals have agreed to shell out $265 mil­lion in an an­titrust case brought against them in Penn­syl­va­nia’s east­ern dis­trict.

In the 2016 law­suit, which has been con­sol­i­dat­ed in­to mul­ti­dis­trict lit­i­ga­tion that in­cludes states, re­tail stores and the in­sur­ance com­pa­ny Hu­mana, the gov­ern­ment al­leged that San­doz and oth­er gener­ic drug man­u­fac­tur­ers vi­o­lat­ed an­titrust laws by en­gag­ing in a “scheme or schemes to fix, main­tain, and sta­bi­lize prices, rig bids, and en­gage in mar­ket and cus­tomer al­lo­ca­tions [of cer­tain] gener­ic phar­ma­ceu­ti­cal prod­ucts.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.